Live Feeds
● TRACKER Updated 5d ago · 8 sources tracked

AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD

AstraZeneca reports that its IL-33 antibody, tozorakimab, significantly reduced COPD exacerbations in the OBERON and TITANIA Phase III trials. The drug showed benefits across various patient groups, including current and former smokers. R&D chief Barr described the results as an internal science success story. The positive late-stage data strengthens the company's prospects for the drug to become a blockbuster treatment for chronic obstructive pulmonary disease.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Tozorakimab demonstrated a statistically significant and clinically meaningful reduction in COPD exacerbations in the OBERON and TITANIA Phase III trials.
  • ✓ The drug showed promise in reducing symptoms for both current and former smokers.
  • ✓ AstraZeneca R&D chief Barr called the IL-33 antibody's performance a science success story.
  • ✓ The drug showed benefits across multiple patient groups.
🛡️ Source Corroboration: 8 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Tozorakimab achieved statistically significant results in two Phase III clinical trials.

Live updates

  1. AstraZeneca's Tozorakimab Reduces COPD Exacerbations in Phase III Trials

    AstraZeneca reports that its IL-33 antibody, tozorakimab, significantly reduced COPD exacerbations in the OBERON and TITANIA Phase III trials. The drug showed benefits across various patient groups, including current and former smokers. R&D chief Barr described the results as an internal science success story. The positive late-stage data strengthens the company's prospects for the drug to become a blockbuster treatment for chronic obstructive pulmonary disease.

    Why it matters

    COPD is a chronic inflammatory lung disease that often leads to sudden worsening of symptoms known as exacerbations. Tozorakimab targets the IL-33 cytokine to manage this inflammation. Success in these trials provides a pathway toward regulatory approval for a new class of COPD therapy.

    What is confirmed

    • Tozorakimab demonstrated a statistically significant and clinically meaningful reduction in COPD exacerbations in the OBERON and TITANIA Phase III trials.
    • The drug showed promise in reducing symptoms for both current and former smokers.
    • AstraZeneca R&D chief Barr called the IL-33 antibody's performance a science success story.
    • The drug showed benefits across multiple patient groups.

    What to watch next

    • Regulatory filing dates for tozorakimab
    • Detailed safety data from the OBERON and TITANIA trials
    Sources used for this update (8)
    1. CNBC — AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
    2. ABC News - Breaking News, Latest News and Videos — New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
    3. WSJ — AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups
    4. AstraZeneca — Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
    5. Fierce Biotech — AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
    6. Endpoints News — Sanofi spells out asthma data, AstraZeneca details COPD win at #ERS26
    7. FirstWord Pharma — AstraZeneca's tozorakimab cuts COPD exacerbations in Phase III studies
    8. Reuters — NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community